NCT02153632 - Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

July 30, 2014

Primary Completion Date

May 20, 2016

Study Completion Date

May 20, 2016

Conditions

Parkinson's DiseaseLevodopa Induced Dyskinesia (LID)

Interventions

DRUG

amantadine HCl ER

Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet

DRUG

Placebo

subjects are given an identical placebo tablet

Trial Locations (56)

11215

Brooklyn

11772

Patchogue

13385

Marseille

27612

Raleigh

31008

Pamplona

33021

Hollywood

33404

North Palm Beach

33612

Tampa

34243

Sarasota

39596

Hindenburg

40502

Miami

Lexington

43004

Columbus

46202

Indianapolis

48103

Ann Arbor

60612

Chicago

65191

Wiesbaden

69677

Bron

70810

Baton Rouge

78681

Round Rock

80304

Boulder

84058

Orem

85724

Tucson

91105

Pasadena

92602

Irvine

92708

Fountain Valley

93001

Ventura

97080

Würzburg

98033

Kirkland

07901

Summit

Unknown

Ottawa

Rennes

Amiens

Clermont-Ferrand

Créteil

Lille

Montauban

Nîmes

Paris

Poitiers

Toulouse

Haag

Erbach im Odenwald

Achim

Bochum

Weissensee

Berlin

Manresa

Seville

Vallés

Alcorcón

Castellana

Marañón

08907

L'Hospitalet de Llobregat

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08195

Hospital General de Cataluna, Barcelona